Clinical Trial News and Research

RSS

C-Path’s TRxA awards $250,000 grant to develop novel treatment for type 1 diabetes

Critical Path Institute's (C-Path) Translational Therapeutics Accelerator (TRxA) proudly announced today a $250,000 grant award aimed at developing a novel treatment for type 1 diabetes (T1D).

19 Jun 2025

New dual-adjuvant vaccine strategy offers hope in the fight against HIV

In the quest to develop an effective HIV vaccine, scientists from Scripps Research have made a significant leap forward. They found that a two-part delivery strategy can train the immune system to produce a stronger response to HIV, offering new hope in the fight against one of the world's most elusive viruses.

19 Jun 2025

New switchable CAR-T therapy enters phase 1 trial for advanced breast cancer

The Calibr-Skaggs Institute for Innovative Medicines, the drug development division of Scripps Research, today announced a milestone in cancer treatment with the dosing of the first patient in a phase 1 trial (NCT06878248) evaluating CLBR001 + ABBV-461, a modular, switchable chimeric antigen receptor T cell (sCAR-T) therapy in patients with advanced or metastatic breast cancer who have no suitable treatment options.

18 Jun 2025

OCCAM Immune and Cancer Research Institute join forces to advance immunotherapy

In a new collaboration that could transform how cancer is treated, OCCAM Immune-a Mount Sinai initiative focused on understanding the immune system's role in disease-is partnering with the Cancer Research Institute (CRI) to unlock the secrets of how the immune system responds to advanced therapies.

17 Jun 2025

Aquatic therapy eases back pain and boosts mental health

A new Concordia study suggests that aquatic therapy for individuals with chronic low back pain can do more than strengthen the muscles around the spine.

17 Jun 2025

Combination therapy may improve health outcomes in adolescents with type 1 diabetes

A clinical trial involving adolescents with type 1 diabetes (T1D) has found a combination therapy may reduce chronic kidney disease and improve health outcomes.

17 Jun 2025

New AI algorithm speeds up cancer diagnosis and treatment decisions

Researchers at VCU Massey Comprehensive Cancer Center have developed a novel algorithm that could provide a revolutionary tool for determining the best options for patients - both in the treatment of cancer and in the prescription of medicines.

17 Jun 2025

Qureight's synthetic study arms validate clinical efficacy in pioneering rare lung disease treatment

Qureight, a deep-learning analytics company accelerating drug development through AI-powered data curation, today announced that its digitally-twinned synthetic control arm has been used in a breakthrough clinical trial application in place of a human placebo group, marking a world-first in lung disease research.

17 Jun 2025

Popular painkiller use linked to gut microbiome shifts

First patient treated in international clinical trial for rare muscle-weakness disease

The first patient enrolled in a planned international clinical trial has been treated at HonorHealth Research Institute with a new type of immune therapy for those with a rare muscle-weakness disease known as Myasthenia Gravis.

16 Jun 2025

Researchers identify a new treatment strategy for neuroblastoma

Researchers at Karolinska Institutet and Lund University in Sweden have identified a new treatment strategy for neuroblastoma, an aggressive form of childhood cancer.

16 Jun 2025

Single-dose of psilocybin shows long-term relief for depression in cancer patients

New results from a clinical trial reveal that a single dose of psilocybin-a naturally occurring psychedelic compound found in mushrooms-can provide sustained reductions in depression and anxiety in individuals with cancer suffering from major depressive disorder.

16 Jun 2025

Video consultations match physical visits for surgical preparation

A video consultation between patient and surgeon is just as good as a physical visit to the outpatient clinic to discuss a major operation.

16 Jun 2025

FDA approval of pembrolizumab marks major shift in head and neck cancer treatment

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test.

15 Jun 2025

Deep B cell depletion offers new hope for rheumatologic and musculoskeletal diseases

CD19-CAR T-cell treatment is a novel option of deep B cell depletion with promising results across different rheumatologic and musculoskeletal diseases (RMD).

15 Jun 2025

Study illustrates a powerful and efficient approach for comparing different standard treatments

A clinical trial led by researchers at The Ottawa Hospital and the University of Ottawa and published in the New England Journal of Medicine illustrates a powerful and efficient approach for comparing different standard treatments.

13 Jun 2025

Boosting CAR T cell survival to improve solid tumor therapy

Chimeric Antigen Receptor (CAR)-T cells are a promising cancer therapy that are made from the patient's own T cells, which are reprogrammed to fight their cancer. One of the limitations of CAR-T cell therapy is the ability of these cells to survive long enough to target the entire tumor.

13 Jun 2025

Empagliflozin preserves kidney function in heart attack patients

SGLT2 inhibitors have become a major drug used to treat diabetes, heart failure, and chronic kidney disease.

13 Jun 2025

New drug combination shows high remission rates in acute myeloid leukemia

A combination therapy that adds a recently approved drug to the current standard of care for newly diagnosed acute myeloid leukemia (AML) showed high rates of complete remission in an early-phase clinical trial conducted at UNC Lineberger Comprehensive Cancer Center and 11 other sites nationwide.

13 Jun 2025

Exercise therapy shows long-term benefits for people with rheumatic diseases

Regular physical activity is increasingly promoted for people with rheumatic and musculoskeletal diseases (RMD) as well as the general population.

13 Jun 2025

Previous
1
...
63
64
65
66
67
68
69
...
1183
Next

Clinical Trial News and Research

C-Path’s TRxA awards $250,000 grant to develop novel treatment for type 1 diabetes

New dual-adjuvant vaccine strategy offers hope in the fight against HIV

New switchable CAR-T therapy enters phase 1 trial for advanced breast cancer

OCCAM Immune and Cancer Research Institute join forces to advance immunotherapy

Aquatic therapy eases back pain and boosts mental health

Combination therapy may improve health outcomes in adolescents with type 1 diabetes

New AI algorithm speeds up cancer diagnosis and treatment decisions

Qureight's synthetic study arms validate clinical efficacy in pioneering rare lung disease treatment

Popular painkiller use linked to gut microbiome shifts

First patient treated in international clinical trial for rare muscle-weakness disease

Researchers identify a new treatment strategy for neuroblastoma

Single-dose of psilocybin shows long-term relief for depression in cancer patients

Video consultations match physical visits for surgical preparation

FDA approval of pembrolizumab marks major shift in head and neck cancer treatment

Deep B cell depletion offers new hope for rheumatologic and musculoskeletal diseases

Study illustrates a powerful and efficient approach for comparing different standard treatments

Boosting CAR T cell survival to improve solid tumor therapy

Empagliflozin preserves kidney function in heart attack patients

New drug combination shows high remission rates in acute myeloid leukemia

Exercise therapy shows long-term benefits for people with rheumatic diseases

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Metabolomics

Improve fermentation and cell culture performance with real-time gas analysis

Scaling patient-derived organoid research

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer